Global Innovative Platforms Inc. 8-K

What Happened

• Global Innovative Platforms Inc. (GIPL) filed an 8-K (Item 5.02) reporting that its Board appointed four new directors effective April 1, 2026: Elyssa Jacob Campbell, James C. Jones, Anthony (Tony) Porter, and David Mauer. The appointments are immediate; the Company will disclose committee assignments and any director compensation in a future filing if determined.

Key Details

• Appointees and backgrounds:
  • Elyssa Jacob Campbell — Chief Executive Officer of Animal Diagnostics and Research Solutions, Inc. since May 2025; Assistant Research Scientist at the University of Georgia since December 2025; previously Laboratory Manager at the University of Georgia (Mar 2019–Nov 2025).
  • James C. Jones — Attorney at the Law Offices of James C. Jones since January 2021.
  • Anthony (Tony) Porter — Managing Director of Bluestar360, LLC since March 2023; Board Advisor to World Wealth Act since May 2025; prior senior roles at Universal Health Services and Methodist LeBonheur Healthcare.
  • David Mauer — President of University Place Partners since 2010; Board Member and Vice President of 40-50 Tenants Corporation since 2005.
• Corporate governance notes: No family relationships among the new directors and current officers; no arrangements or understandings related to these appointments.
• Related-party disclosure: No transactions since the start of the Company’s last fiscal year, and none proposed, involving any of the new directors (or immediate family) that would require Item 404(a) disclosure.

Why It Matters

• Board composition changed with four additions, bringing experience in animal health research, legal practice, healthcare operations, and partnership management. For investors, this can affect governance and oversight as GIPL advances its breath-based diagnostics and other strategic initiatives. The Company’s note that committee roles and compensation will be reported later means governance details and director influence are forthcoming.